Yazar "Tural, Deniz" için listeleme
-
Prognostic factors in patients with metastatic urothelial carcinoma who have been treated with atezolizumab
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Özhan, Nail; Akar, Ebru; Çakar, Bilge; Köstek, Osman; Ekenel, Mahmut; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy, Fatma; Oruç, Korkmaz; Bayram, Süleyman Nuri; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Artaç, Macide (Elsevier, 2020)Background: In the current study, we evaluated pretreatment prognostic factors foroverall survival (OS) in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy in the Expanded-Access ... -
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with atezolizumab
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Özhan, Nail; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Paksoy, Nail; Dirican, Ahmet; Erdem, Dilek; Selam, Meltem; Tanrıverdi, Özgür; Paydaş, Semra; Urakçı, Zuhat; Atağ, Elif; Güncan, Sabri; Ürün, Yüksel; Alkan, Ali; Kaya, Ali Osman; Tataroğlu Özyükseler, Deniz; Taşkaynatan, Halil; Yıldırım, Mustafa; Sönmez, Müge; Başoğlu, Tuğba; Gündüz, Şeyda; Kılıçkap, Saadettin; Artaç, Mehmet (Springer Japan KK, 2021)Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab ... -
Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study
Bilici, Ahmet; Uysal, Mükremin; Menekşe, Serkan; Akın, Semih; Yıldız, Fatih; Turan, Merve; Sezgin Göksu, Sema; Beypınar, İsmail; Sakalar, Teoman; Değirmenci, Mustafa; Erdem, Dilek; Başaran, Gül; Ölmez, Ömer Fatih; Avcı, Nilüfer; Tural, Deniz; Sakin, Abdullah; Türker, Sema; Demir, Atakan; Temiz, Süleyman; Kaplan, Muhammed Ali; Doğan, Mutlu; Tanrıverdi, Özgür; Bilgetekin, İrem; Yeşil Çınkır, Havva; Açıkgöz, Özgür; Paydaş, Semra; Uslu, Rüçhan; Turhal, Serdar (Taylor & Francis Inc, 2022)Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) ... -
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Kılıçkap, Sadettin; Atcı, Muhammed Mustafa; Kahraman, Seda; Keskinkılıç, Merve; Bilgetekin, İrem; Ayhan, Murat; Tural, Deniz; Eren, Önder; Akkoç Mustafayev, Fatma Nihan; Yaman, Şebnem; Tatlı, Ali Murat; Bayram, Ertuğrul; Kutlu, Yasin; Ertürk, İsmail; Özcan, Erkan; Gülmez, Ahmet; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Akın Telli, Tuğba; Aksoy, Asude; Üskent, Necdet; İriağaç, Yakup; Köse Baytemür, Naziyet; Aydın, Dinçer; Sakalar, Teoman; Arak, Haci; Selçukbiricik, Fatih; Ergün, Yakup; Korkmaz, Taner; Ak, Naziye; Ünal, Çağlar; Akdeniz, Nadiye; Özgün, Mehmet Alpaslan; Öksüzoğlu, Berna; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Future Medicine Ltd., 2022)Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell ... -
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC
Yıldırım, Mahmut Emre; Karaca, Mustafa; Artaç, Mehmet; Çiçin, İrfan; Geredeli, Çağlayan; Alacacıoğlu, Ahmet; Tanrıkulu Şimşek, Eda; Bilici, Ahmet; Harputluoğlu, Hakan; Özçelik, Melike; Bozkurt, Oktay; Yüksel, Sinemiş; Tural, Deniz; Sakin, Abdullah; Çil, Timuçin; Öven, Bala Başak; Dane, Faysal; Çevik, Duygu; Gümüş, Mahmut; Işıkdogan, Abdurrahman (Lippincott Williams and Wilkins, 2022)... -
Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma
Tural, Deniz; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Erman, Mustafa; Coşkun, Hasan Şenol; Artaç, Mehmet; Kılıçkap, Saadettin (Springer, 2022)Background Atezolizumab (ATZ) has demonstrated antitumor activity in previous studies in patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of ATZ was modest. Therefore, finding ... -
What is the optimal treatment in clinical stage T3N0M0 rectal cancer?
Tural, Deniz; Yıldız, Özcan; Elçin, Olgun; Erdamar, Sibel; Güney, Sabri; Demireli, Fuat; Büyükünal, Evin; Serdengeçti, Süheyla (Zerbinis Medical Publications, 2014)Purpose: Some previous studies suggested that certain rectal cancer patients with stage T3N0 and favorable features may be adequately treated with surgery and adjuvant chemotherapy. However, the optimal management of ...